Marshall Wace LLP Has $67.81 Million Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Marshall Wace LLP cut its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 1.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,172,593 shares of the company's stock after selling 42,623 shares during the period. Marshall Wace LLP owned about 0.37% of Teva Pharmaceutical Industries worth $67,805,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. New Covenant Trust Company N.A. acquired a new stake in Teva Pharmaceutical Industries during the 1st quarter valued at $28,000. EntryPoint Capital LLC acquired a new stake in Teva Pharmaceutical Industries during the 1st quarter valued at $30,000. Beach Investment Counsel Inc. PA acquired a new stake in Teva Pharmaceutical Industries during the 2nd quarter valued at $48,000. Byrne Asset Management LLC acquired a new stake in Teva Pharmaceutical Industries during the 2nd quarter valued at $52,000. Finally, Industrial Alliance Investment Management Inc. acquired a new stake in Teva Pharmaceutical Industries during the 1st quarter valued at $54,000. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Trading Down 1.5 %

Shares of NYSE TEVA traded down $0.27 during midday trading on Wednesday, hitting $17.46. The stock had a trading volume of 4,900,969 shares, compared to its average volume of 9,874,284. Teva Pharmaceutical Industries Limited has a fifty-two week low of $8.06 and a fifty-two week high of $19.08. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.59. The firm has a market cap of $19.78 billion, a P/E ratio of -42.59, a price-to-earnings-growth ratio of 1.23 and a beta of 0.88. The company's 50-day simple moving average is $17.72 and its 200 day simple moving average is $16.17.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.03. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. The business had revenue of $4.16 billion for the quarter, compared to analyst estimates of $3.99 billion. Research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.33 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on TEVA shares. Barclays raised their price target on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the company an "overweight" rating in a report on Thursday, August 1st. UBS Group raised their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a "buy" rating in a report on Tuesday, September 3rd. StockNews.com cut Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a report on Monday. Argus raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and set a $20.00 price target for the company in a report on Wednesday, July 10th. Finally, Jefferies Financial Group lifted their target price on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a "buy" rating in a research note on Thursday, June 27th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $18.89.

Insider Transactions at Teva Pharmaceutical Industries

In other news, insider Eric A. Hughes sold 24,537 shares of the firm's stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total value of $423,263.25. Following the transaction, the insider now directly owns 45,060 shares in the company, valued at approximately $777,285. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.55% of the stock is owned by corporate insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.